Clinicians Report Peptide Serum Enhances Results of Botox Injections for Wrinkle Reduction
Seven clinicians reported that a topical serum containing neuropeptides like acetyl hexapeptide-8 appeared to complement botulinum toxin injections by further improving skin radiance and reducing fine lines and wrinkles.
Quick Facts
What This Study Found
A topical neuropeptide serum containing 2% acetyl hexapeptide-8, 2% dipeptide diaminobutyroyl, 5% polyhydroxy acids, 5% niacinamide, and 1% laminaria extract appeared to complement botulinum toxin type-A (BTX-A) injections in real-world clinical use. Seven clinicians (5 dermatologists and 2 surgeons) reported that the combination improved skin radiance, reduced fine lines, and reduced wrinkles in diverse patients when the serum was applied twice daily alongside BTX-A injections. The serum reportedly works by stimulating 9 key skin biomarkers.
Key Numbers
2% acetyl hexapeptide-8 · 2% dipeptide diaminobutyroyl · 5% PHA · 5% niacinamide · 1% laminaria extract · 7 clinicians · 9 skin biomarkers targeted · Twice daily application
How They Did This
Real-world clinical case series from 5 dermatologists and 2 surgeons reporting their experiences using a topical neuropeptide serum (TNP-serum) in combination with botulinum toxin type-A injections. Patients applied the serum twice daily as part of an integrated skincare regimen. This is observational reporting of clinical experience, not a controlled trial.
Why This Research Matters
Botulinum toxin injections are widely used for wrinkle reduction but address only muscle-related lines. Combining injectable treatments with topical peptide serums could offer a more comprehensive approach to facial rejuvenation. This real-world evidence from multiple experienced clinicians suggests peptide-based skincare may provide additive benefits to standard cosmetic procedures.
The Bigger Picture
The cosmetic peptide skincare market is rapidly growing, with peptides like acetyl hexapeptide-8 among the most popular active ingredients. This report adds to the growing body of real-world evidence that topical peptide formulations may complement injectable cosmetic procedures, though rigorous controlled trials remain limited in this space.
What This Study Doesn't Tell Us
This is a case series based on clinician observations, not a controlled clinical trial. There is no placebo or comparator group, no blinding, and no standardized outcome measures. The number of patients treated is not specified. As a journal supplement article, the publication format raises questions about potential industry sponsorship or influence.
Questions This Raises
- ?Would a randomized controlled trial with standardized outcome measures confirm the additive benefit of this peptide serum over BTX-A alone?
- ?Which of the serum's active ingredients contributes most to the observed improvements — the peptides, niacinamide, or the combination?
- ?How long do the additive benefits persist, and does continued serum use extend the interval between BTX-A injection sessions?
Trust & Context
- Key Stat:
- 7 clinicians across 5 specialties Reported complementary benefits of a topical neuropeptide serum used twice daily alongside botulinum toxin injections in diverse patients
- Evidence Grade:
- This is a case series of clinician observations without controls, blinding, or standardized measurements — one of the weakest forms of clinical evidence. While the clinical experience is informative, the findings cannot establish causation or rule out placebo effects.
- Study Age:
- Published in 2024, this reflects current clinical practice in cosmetic dermatology. The use of peptide-based topicals alongside injectables is a growing trend in aesthetic medicine.
- Original Title:
- INDIVIDUAL ARTICLE: Real-World Clinical Experience With a Neuro-Peptide Serum in Combination With Botulinum Toxin Type-A Injections.
- Published In:
- Journal of drugs in dermatology : JDD, 23(11), 43661s3-43661s14 (2024)
- Authors:
- Lupin, Mark, Bjerring, Peter, Andriessen, Anneke, Chantrey, Jonquille, Fabi, Sabrina Guillen, Liew, Steven, McDonald, Cara, Xiaolei, Qin, White, Stacy
- Database ID:
- RPEP-08781
Evidence Hierarchy
Frequently Asked Questions
What is acetyl hexapeptide-8 and why is it sometimes called 'topical Botox'?
Acetyl hexapeptide-8 (also known as Argireline) is a synthetic peptide made of six amino acids. It's nicknamed 'topical Botox' because it's thought to work similarly — by reducing the signals that cause muscles to contract, potentially softening expression lines. However, its effects are much milder than injectable botulinum toxin, and it works at the skin surface rather than at the neuromuscular junction.
Is there strong evidence that peptide serums improve the results of Botox injections?
The evidence is currently limited to clinician observations and case reports like this one. While practitioners report benefits, no large randomized controlled trials have definitively proven that peptide serums add measurable improvement over BTX-A injections alone. The serum also contains non-peptide ingredients like niacinamide that have their own skin benefits, making it difficult to isolate the peptide effect.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08781APA
Lupin, Mark; Bjerring, Peter; Andriessen, Anneke; Chantrey, Jonquille; Fabi, Sabrina Guillen; Liew, Steven; McDonald, Cara; Xiaolei, Qin; White, Stacy. (2024). INDIVIDUAL ARTICLE: Real-World Clinical Experience With a Neuro-Peptide Serum in Combination With Botulinum Toxin Type-A Injections.. Journal of drugs in dermatology : JDD, 23(11), 43661s3-43661s14.
MLA
Lupin, Mark, et al. "INDIVIDUAL ARTICLE: Real-World Clinical Experience With a Neuro-Peptide Serum in Combination With Botulinum Toxin Type-A Injections.." Journal of drugs in dermatology : JDD, 2024.
RethinkPeptides
RethinkPeptides Research Database. "INDIVIDUAL ARTICLE: Real-World Clinical Experience With a Ne..." RPEP-08781. Retrieved from https://rethinkpeptides.com/research/lupin-2024-individual-article-realworld-clinical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.